Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选择性雌激素受体调节剂,为预防绝经后骨质疏松症药物。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选择性雌激素受体调节剂,为预防绝经后骨质疏松症药物。
声明:上例句、词性分类均由互联网资源自动生成,部分未经过人工审
,其表达内容亦不代表本软件
;若发现问题,欢迎向我们指正。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选择素受体调节剂,为预防绝
后骨质疏松症药物。
声明:上例句、词
分类均由互联网资源自动生成,部分未
工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选择性雌激素受体,为预防绝经后骨质疏松症药物。
声明:上例句、词性分类均由互联网资源自
,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选择性雌激素受体调,
预防绝经后骨质疏松症药物。
声明:上例句、词性分类均由互联网资源
成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
芬是一种选择性雌激素受体调节剂,为预防绝经后骨质疏松症药物。
声明:上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达
不代表本软件的观点;若发现问题,欢迎向我们指正。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
卓昔芬是一种选择性雌激素受体调节剂,为预防绝经后骨质疏松症药物。
声明:上例
、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容
表本软件的观点;若发现问题,欢迎向我们指正。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选择性雌激素受体调节剂,为预防绝经后骨质疏松症药物。
声明:上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表
软件
观点;若发现问题,欢迎向我们指正。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
昔芬是一种选择性雌激素受体调节剂,为预防绝经后骨质疏松症药物。
声明:上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内
代表本软件的观点;若发现问题,欢迎向我们指正。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选择性雌激素受体调节剂,为预防绝经后骨质疏松症药物。
声明:上例句、词性分类均由互联网资源自动生成,部分未经过人工审
,其表达内容亦不代表本软件
;若发现问题,欢迎向我们指正。